By Ben Hirschler - Analysis
LONDON (Reuters) - The pharmaceutical industry is starting to heal.
After a barren few years, a recent batch of product approvals and some surprisingly good clinical trial news has revived hopes the sector can return to growth after its well-flagged “cliff” of patent expiries.
“There have certainly been a number of successes,” said Andy Smith, a healthcare fund manager with Axa Framlington in London. “Is it going to replenish losses from the enormous patent cliff? Not yet, but it is a good sign on the way.”
Over the next four years the industry will face the biggest losses to generics in its history, leaving many companies struggling to replace both sales and profits.
Until now, investors have attributed little value to new drugs in the pipeline because of doubts if they will get past increasingly safety-conscious regulators.
But things may be improving. In the second quarter of 2009, the U.S. Food and Drug Administration (FDA) approved 13 new molecules, twice the average of six in previous four quarters.
Morgan Stanley analysts believe a U.S. Supreme Court ruling in March that drugmakers can be held liable for harm from medicines despite an FDA approval has made the agency less risk-averse.
The roster of new drugs licensed for sale since March includes some big surprises, such as Vanda Pharmaceuticals’s (VNDA.O) schizophrenia drug Fanapt, as well as previously delayed heart drugs Effient from Eli Lilly (LLY.N) and Daiichi Sankyo (4568.T), and Sanofi-Aventis’s (SASY.PA) Multaq.
Biotech drugs, meanwhile, have delivered some stunningly positive clinical trial results -- notably Human Genome Sciences’s HGSI.O Benlysta for lupus, Amgen’s (AMGN.O) bone drug denosumab and Dendreon’s DNDN.O cancer vaccine Provenge.
GlaxoSmithKline (GSK.L) is a partner for both Benlysta and denomsumab. Dendreon is currently scouting for a collaborator.
Thomas Kaufmann, a buy-side analyst at Credit Suisse Private Banking in Zurich, said recent news could prompt a rethink about the sector as investors look again at beaten-down stock prices.
“It could be a turning point for the industry in terms of stock valuations, which are at historically depressed levels for pharmaceutical companies because investors assume nothing or hardly anything will be coming out of the pipeline,” he said.
European drug stocks currently trade at a price-to-earnings discount of more than 10 percent to the wider market, against a typical premium over the past decade of around 40 percent.
Not all companies are finding the going easy, however. Novo Nordisk (NOVOb.CO), for example, is still awaiting a U.S. nod for Victoza, a new diabetes drug already on sale in Europe.
Attention will turn next to the peak autumn medical conference season where clinical data on many upcoming drugs will be showcased.
One of the first in the spotlight will be AstraZeneca’s new blood thinner Brilinta, a rival to Plavix from Sanofi and Bristol, data for which will be presented at a cardiology meeting in Barcelona later this month.
Taken as a whole, the recent pick-up in approvals and a slew of data releases before the end of the year “hints at the return of pipeline potential to the broader investment debate,” Citigroup analysts said.
The industry certainly needs a tonic. Despite windfall gains this year from pandemic flu and generally better-than-expected second-quarter results, underscoring healthcare’s relative resilience, drug companies faces a painful period of adjustment.
Pfizer (PFE.N) and Sanofi, two of the companies facing the biggest generic hits as cholesterol fighter Lipitor and Plavix go off patent, have sought to put a floor under their patent cliffs by guiding on earnings right out to 2012 and 2013.
Others, however, are unlikely to follow with such long-term forecasts, especially with U.S. healthcare reform adding to uncertainty, even if the worst fears on that front have abated.
“Many companies increasingly prefer not to commit to a number if they believe the consensus is broadly in line okay,” said Simon Friend, global pharmaceuticals leader at PricewaterhouseCoopers.
Thomson Reuters data suggests Swiss drugmakers Roche ROG.VX and Novartis NOVN.VX have the best view from the top of the patent cliff, based on consensus forecasts for sales and earnings out to 2013.
The big unknown is whether drug companies’ big bets on the medicines of tomorrow will exceed or fall short of expectations.
Kaufmann from Credit Suisse is hopeful. “Sooner or later drug companies will come up with new drugs and they will hit the market and they can be just as profitable as the old ones have been,” he said.
Editing by Sitaraman Shankar